Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin 18 pseudogene 56 (KRT18P56) is a member of the large family of human keratin pseudogenes. Pseudogenes are non-coding genomic sequences that are homologous to functional genes but lack protein-coding ability due to mutations, deletions, or insertions[1]. KRT18P56 is related to the canonical keratin 18 gene, which encodes type I intermediate filament protein involved in epithelial cell structure and stress response, but unlike the functional gene, KRT18P56 does not encode a protein and is not known to participate in any biological process, disease mechanism, or serve as a therapeutic target. There is no current scientific basis to consider KRT18P56 an actionable target in research, diagnostics, or therapy[1][6]. If you intended the protein-coding keratin 18 gene (KRT18), this is a different entity and is considered a legitimate therapeutic and diagnostic target[2][3][5]. However, KRT18P56 specifically denotes a pseudogene and does not meet criteria as a molecular target.
None; does not encode a targetable entity with a mechanism of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratin 18 pseudogene 56 (KRT18P56).